Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
Anyone who thinks that AVCT are exclusively a Covid share needs to take a very careful look at the Placing presentation BBN posted earlier. Some of the potential revenue streams to come are quite mind boggling. Covid has provided the PR and potential revenue but it is the potential treatment and diagnosis of more long standing illnesses like cancer which are of greatest significance to not only AVCT but the wider population
No specific monies allocated to the development of the neutralising treatment so it leaves open the possibility of a major JV deal to finance this
Joining up the dots it cannot now be doubted after this RNS today following the Medusa deal before this that the AVCT lateral flow test works and is highly likely to be a huge commercial success.
Couldn’t see anything in the RNS re finance to develop affimer for the neutralising treatment which may well suggest a link up with a big Pharma company announcement may not be too far away
Yes I was disappointed with this news having taken Alastair at his word and topped up at a much higher price this week but if it brings forward the potential cancer treatment trials to an earlier date then I can live with that
The fact that the next news will be on performance as opposed to a stage in the process is firstly an explanation as to why the next RNS will take a little longer to arrive and secondly have a much greater impact on the SP not least because if successful it will further de-risk the whole affimer platform
Noticed on Twitter that Myles McNulty has very recently bought into BMN partly on BBN’s write up on his 2 key Alpha stocks at the moment: BMN and AVCT. Now he has made a few quid on AIM in the past with a good track record and a good following some of whom will follow him to BMN
Given the PM’s reference to pregnancy tests today and the ODX saga, can you imagine the impact on our SP tomorrow if there was a positive update On either of our POC saliva tests in the morning.
IES still flying so that may also be a factor
People who put stop losses within 10% of the closing price have no understanding of how market makers particularly in the AIM market work. They can see where the stop losses are, drop the price take out the stop loss with NT to buy at that price and then raise the price again. Rinse and repeat the following day. Easy money for them
You are making the assumption that Avacta is the only firm in Yorkshire worth investing in. As a Tyke I would take exception to that!
Looking forward to Part 2 and 3 before the market opens again on Tuesday particularly his views on the potential neutralising impact of the attimer protein
Prototype BAMS test ready next week with first sales next month followed by the lateral test from mid July. Exciting times ahead
A very exciting read !
People have been rightly concentrating on the short term significance to Avacta of both its diagnostic kit and the potential treatment through its neutralising agent. Of longer term significance is the de risking of its whole affimer platform If this is successful. Once this outbreak is over the world’s attention will then move to the next potential pandemic and how to counteract this more effectively. Does Alistair’s video demonstration yesterday as to how the outer core of the binding attimer protein can be adapted to counteract any mutations or new viruses that come along provide one possible answer to any future pandemics? Next week may provide the answer as to which of the big pharmaceutical companies will join us in developing this treatment
Drifter, they did not advertise a dividend as you suggest but announced a dividend policy which very clearly stated that the company would pay a divi out of cash flow at an appropriate time. I would suggest that in the middle of a worldwide pandemic with V prices relatively low, production disrupted and other demands on cash flow now is not an appropriate time
The key takeaway from this morning’s Presentation was the last minute when Alastair was talking about the ongoing discussions with a Major regarding a JV on developing the neutralising affimer as a Treatment for CV. Expect an announcement on this next week which will put a ?? up the SP. Watch for the reloading up this pm.
Alastair is a natural communicator who is able to explain complex technical issues in an understandable way to the lay person. One of the best companies I have been involved with for PR
There was a significant minority of people yesterday criticising the marketing deal with the founders of Boohoo. One of the many advantages of that tie up can be seen today when without exception all the publicity today has been headlined by the billionaire Boohoo links to Avacta’s new testing facility.
Just out. Very positive and expects the prototype test to be out by the end of May